Overall | H101 | Control | P-Value | Overall Survival(%) | Median survival(mo) | Univariate | Multivariate | |||
---|---|---|---|---|---|---|---|---|---|---|
1-yr | 2-yr | P-Value | ExpB (Hazard Ratio ,95 % CI) | P-Value | ||||||
Gender | 0.305 | 0.302 | ||||||||
Male | 159 | 81 | 78 | 67 | 52 | 13.0 | ||||
Female | 16 | 6 | 10 | 60 | 30 | 11.2 | ||||
Age | 0.948 | 0.100 | ||||||||
Median | 55.0 | 55.0 | 54.5 | |||||||
< 60 | 114 | 59 | 55 | 68 | 49 | 12.5 | ||||
≥ 60 | 61 | 28 | 33 | 68 | 56 | 13.0 | ||||
Alpha-foetoprotein(ng/ml) | 0.316 | |||||||||
307.2 | 269.1 | 307.2 | ||||||||
Alpha-foetoprotein(ng/ml) | 0.947 | 0.06 | 1.669(1.178–2.366) | 0.004 | ||||||
≤ 20 | 53(30.1 %) | 27(30.7) | 26(29.5) | 89 | 81 | 17.6 | ||||
20–400 | 42(23.9 %) | 20(22.7) | 22(25.0) | 60 | 45 | 13.9 | ||||
≥ 400 | 80(45.5 %) | 40(45.5) | 40(45.5) | 52 | 32 | 9.1 | ||||
Child Pugh grade | 0.820 | 0.007 | 2.132(1.138–3.995) | 0.018 | ||||||
A | 154(88.0 %) | 76(87.3 %) | 78(88.6 %) | 70 | 55 | 13.3 | ||||
B | 21(12.0 %) | 11(12.6) | 10(11.3) | 38 | 25 | 7.7 | ||||
ALB(g/L) | 0.228 | 0.412 | ||||||||
Median | 40.0 | 39.6 | 40.2 | |||||||
≥ 35 | 131 | 61 | 70 | 0.166 | 62 | 50 | 11.7 | |||
< 35 | 44 | 26 | 18 | 67 | 52 | 13.3 | ||||
Tbil(U/L) | 0.386 | 0.003 | ||||||||
Median | 16.4 | 16.1 | 16.8 | |||||||
< 20 | 119 | 61 | 58 | 0.628 | 75 | 56 | 13.7 | |||
≥ 20 | 56 | 26 | 30 | 48 | 40 | 8.0 | ||||
Virus infection | 0.970 | 0.101 | ||||||||
none | 15 | 7 | 8 | 88 | 66 | 13.6 | ||||
HBV | 158 | 79 | 79 | 63 | 51 | 12.6 | ||||
HCV | 2 | 1 | 1 | 50 | 0 | 13.9 | ||||
Platelet count (10E9/L) | 0.630 | 0.676 | ||||||||
Median | 167.0 | 179.2 | 154.5 | |||||||
< 100 | 31 | 11 | 20 | 0.112 | 63 | 46 | 12.2 | 0.330(0.141–0.773) | 0.011 | |
≥ 100 | 144 | 76 | 68 | 67 | 53 | 12.8 | ||||
No. of tumours | 1.000 | <0.001 | 2.024(1.127–3.633) | 0.018 | ||||||
≤ 3 | 127 | 69 | 70 | 74 | 57 | 13.7 | ||||
> 3 | 36 | 18 | 18 | 38 | 30 | 7.6 | ||||
Tumour size (cm) | 0.730 | 0.028 | 2.936(1.297–6.650) | 0.010 | ||||||
≤ 5 | 45 | 21 | 24 | 91 | 75 | 18.1 | ||||
> 5 | 130 | 66 | 64 | 56 | 42 | 9.8 | ||||
Anti-HBV therapy | 0.197 | 0.424 | ||||||||
Yes | 56 | 32 | 24 | 60 | 54 | 13.3 | ||||
No | 119 | 55 | 64 | 69 | 51 | 9.65 | ||||
H101 | 0.046 | 0.042 | 0.593(0.353–0.995) | 0.048 | ||||||
Yes | 87 | 87 | 0 | 69 | 60 | 12.8 | ||||
No | 88 | 0 | 88 | 60 | 44 | 11.6 | ||||
BCLC stage | 0.453 | 0.001 | 2.168(1.322–3.557) | 0.002 | ||||||
A3 | 1 | 0 | 1 | |||||||
A4 | 17 | 10 | 7 | 94 | 94 | 17.0 | ||||
B | 108 | 50 | 58 | 72 | 56 | 12.96 | ||||
C | 49 | 27 | 22 | 52 | 23 | 6.96 |